Company / R&D Expense
CRISPR Therapeutics AG R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$284.8M
FY2025
5-year range
$284.8M / $461.6M
FY2021-FY2025
Trend
-8.2%
vs FY2024
Sector context
#64 of 209
Health Care
What the data says
At $285M, CRISPR Therapeutics AG's r&d expense ranks #64 of 209 in the Health Care sector. R&D Expense has declined for 3 consecutive years, from $462M in FY2022 to $285M in FY2025.
Based on SEC 10-K filings.
$285M in FY2025 with a 5-year CAGR of +5.2%.
Declined from $387M to $285M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -14.9%
- 5-Year CAGR
- +5.2%
- 10-Year CAGR
- -
Sector benchmark
#64 of 209 in Health CareTop 31% of 209This company $284.8M Sector average $647.6M
▼
-56.0% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's r&d expense has declined for 3 consecutive years.
- 5-year CAGR of +5.2%, indicating consistent growth.
- In FY2025, r&d expense decreased 8.2% year-over-year.
- Ranks #64 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $284.8M | -8.2% |
| FY2024 | $310.2M | -19.9% |
| FY2023 | $387.3M | -16.1% |
| FY2022 | $461.6M | +35.6% |
| FY2021 | $340.6M | +53.8% |
| FY2020 | $221.4M | +23.4% |
| FY2019 | $179.4M | +57.6% |
| FY2018 | $113.8M | +63.0% |
| FY2017 | $69.8M | +65.3% |
| FY2016 | $42.2M | +235.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026